Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Cognition Therapeutics, Inc. Common Stock (CGTX)

Biological Products, (no Disgnostic Substances)

https://www.cogrx.com

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

2403 SIDNEY STREET, SUITE 261
PITTSBURGH, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/08/2021

Market Cap

29,002,354

Shares Outstanding

32,119,999

Weighted SO

32,121,864

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

RVPHW --.--%

EYEN --.--%

RNAZ --.--%

KOD --.--%

TFFP --.--%

TCRX --.--%

CUE --.--%

DRMA --.--%

GANX --.--%

Beta

1.4470

Last Div

0.0000

Range

0.542-2.95

Chg

0.0820

Avg Vol

935319

Mkt Cap

29002354

Exch

NASDAQ

Country

US

Phone

412 481 2210

DCF Diff

-0.2666

DCF

0.9906

Div Yield

0.0000

P/S

77.9633

EV Multiple

-0.0217

P/FV

1.2606

Div Yield %

0.0000

P/E

-0.9332

PEG

0.0003

Payout

0.0000

Current Ratio

3.0723

Quick Ratio

3.0723

Cash Ratio

2.6129

DSO

3040.6855

DIO

0.0000

Op Cycle

3040.6855

DPO

4325.8203

CCC

-1285.1348

Gross Margin

0.3118

Op Margin

-157.8333

Pretax Margin

-83.5538

Net Margin

-83.5538

Eff Tax Rate

-0.0845

ROA

-0.9044

ROE

-1.1811

ROCE

-2.5039

NI/EBT

1.0000

EBT/EBIT

0.5294

EBIT/Rev

-157.8333

Debt Ratio

0.0182

D/E

0.0271

LT Debt/Cap

0.0188

Total Debt/Cap

0.0264

Int Coverage

-4193.8571

CF/Debt

-36.6314

Equity Multi

1.4937

Rec Turnover

0.1200

Pay Turnover

0.0844

Inv Turnover

0.0000

FA Turnover

0.4542

Asset Turnover

0.0108

OCF/Share

-0.5706

FCF/Share

-0.5728

Cash/Share

0.7122

OCF/Sales

-61.4462

FCF/OCF

1.0040

CF Coverage

-36.6314

ST Coverage

-124.2283

CapEx Coverage

-251.1868

Div&CapEx Cov

-251.1868

P/BV

1.2606

P/B

1.2606

P/S

77.9633

P/E

-0.9332

P/FCF

-1.2638

P/OCF

-1.2689

P/CF

-1.2689

PEG

0.0003

P/S

77.9633

EV Multiple

-0.0217

P/FV

1.2606

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Aug 23, 22:04 Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office GlobeNewswire Inc. Jan 04, 07:30 Cognition Therapeutics CEO Issues Letter to Shareholders GlobeNewswire Inc. Nov 16, 07:30 Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens GlobeNewswire Inc. Nov 15, 07:30 Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases GlobeNewswire Inc. Nov 07, 07:30 Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease GlobeNewswire Inc. Nov 02, 07:30 Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update GlobeNewswire Inc. Oct 27, 07:30 Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD GlobeNewswire Inc. Oct 24, 16:30 Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

Revenue Product Segmentation